The trihydride complexes [Cp*RuH(3)(kappa(1)-P-(i)Pr(2)PCH(2)X)] [X = pyridine (Py), 2a; quinoline (Quin), 2b] have been prepared by reaction of the corresponding chloro derivatives [Cp*RuCl(kappa(2)-P,N-(i)Pr(2)PCH(2)X)] [X = Py (1a), Quin (1b)] with NaBH(4) in methanol. Both 2a and 2b exhibit quantum-mechanical exchange coupling. The proton-transfer reactions to 2a and 2b using strong as well as weak proton donors have been experimentally and computationally studied. Density functional theory studies have been performed to analyze the stability of the proposed species, the hydrogen exchange, and the protonation pathway. The reactions with weak donors such as PhCOOH, indole, or salicylic acid in benzene or toluene result in the formation of hydrogen-bonded adducts between the proton donor and the pendant pyridine or quinoline group. However, in a more polar solvent such as dichloromethane, there is spectral evidence for the proton transfer to the hydride to yield a dihydrogen complex. The protonation with CF(3)SO(3)H in CD(2)Cl(2) occurs in a stepwise manner. In a first step, the pendant pyridine or quinoline group is protonated to yield [Cp*RuH(3)(kappa(1)-P-(i)Pr(2)PCH(2)XH)](+) [X = Py (4a) or Quin (4b)]. The NH proton is then transferred to the hydride and one molecule of dihydrogen is released, furnishing the cationic mono(dihydrogen) complexes [Cp*Ru(H(2))(kappa(2)-P,N-(i)Pr(2)PCH(2)X)](+) [X = Py (5a) or Quin (5b)]. These species are thermally stable and do not undergo irreversible rearrangement to their dihydride isomers. In the presence of an excess of acid, a second protonation occurs at the hydride site and the dicationic complexes [Cp*RuH(4)(kappa(1)-P,N-(i)Pr(2)PCH(2)XH)](2+) [X = Py (6a) or Quin (6b)] are generated. These species are stable up to 273 K and consist of equilibrium mixtures between bis(dihydrogen) and dihydrido(dihydrogen) tautomeric forms. Above this temperature, 6a and 6b are converted into the corresponding cationic mono(dihydrogen) complexes 5a/5b. The crystal structures of [Cp*RuCl(kappa(2)-P,N-(i)Pr(2)PCH(2)Quin)] (1b), [Cp*RuH(3)(kappa(1)-P-(i)Pr(2)PCH(2)Quin)] (2b), [Cp*RuH(3)(kappa(1)-P-(i)Pr(2)PCH(2)Py...H...OOCC(6)H(4)OH)] (3a), [Cp*Ru(H(2))(kappa(2)-P,N-(i)Pr(2)PCH(2)Quin)][BAr'(4)] (5b), [Cp*Ru(N(2))(kappa(2)-P,N-(i)Pr(2)PCH(2)Quin)][BAr'(4)] (8b), and [Cp*Ru(O(2))(kappa(2)-P,N-(i)Pr(2)PCH(2)Quin)][BAr'(4)] (9b) are reported.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/ic100710d | DOI Listing |
Int J Mol Sci
December 2024
Lipid Pathobiochemistry Group, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
Hepatocellular carcinoma () is one of the leading causes of cancer deaths due to its late diagnosis and restricted therapeutic options. Therefore, the search for appropriate alternatives to commonly applied therapies remains an area of high clinical need. Here we investigated the therapeutic potential of the glucosylceramide synthase (GCS) inhibitor Genz-123346 and the cationic amphiphilic drug aripiprazole on the inhibition of Huh7 and Hepa 1-6 hepatocellular cancer cell and tumor microsphere growth.
View Article and Find Full Text PDFPediatr Pulmonol
January 2025
Beatrix Children's Hospital Department of Pediatric Pulmonology and Pediatric Allergy, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Introduction: Lumacaftor/ivacaftor (lum/iva) was introduced in the Netherlands in 2017. We investigated 1-year efficacy of lum/iva on lung function and small airway and structural lung disease evaluated by multiple breath nitrogen washout and CT scan. Additionally, we investigated effects of lum/iva on exacerbations, anthropometry, sweat chloride and safety in children with CF in the Netherlands.
View Article and Find Full Text PDFSci Rep
January 2025
PredictCan Biotechnologies SAS, Biopôle Euromédecine, Grabels, France.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Treating HCC is challenging because of the poor drug effectiveness and the lack of tools to predict patient responses. To resolve these issues, we established a patient-centric spheroid model using HepG2, TWNT-1, and THP-1 co-culture, that mimics HCC phenotype.
View Article and Find Full Text PDFAnticancer Agents Med Chem
January 2025
Department of Pharmaceutics, College of Pharmacy, Jazan University, Saudi Arabia.
Nitrogen-based organic heterocyclic compounds are an important source of therapeutic agents. About 75% of drugs approved by the FDA and currently available in the market are N-heterocyclic organic compounds. The N-heterocyclic organic compounds like pyridine, indole, triazoles, triazine, imidazoles, benzimidazoles, quinazolines, pyrazoles, quinolines, pyrimidines, porphyrin, etc.
View Article and Find Full Text PDFPharmaceuticals (Basel)
December 2024
Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.
Background: Recently, pyrido[2,3-] pyrimidine, triazolopyrimidine, thiazolopyrimidine, quinoline, and pyrazole derivatives have gained attention due to their diverse biological activities, including antimicrobial, antioxidant, antitubercular, antitumor, anti-inflammatory, and antiviral effects.
Objective: The synthesis of new heterocyclic compounds including 5-quinoline-pyrido[2,3-] pyrimidinone (-, , -), 6-quinoline-pyrido[2,3-]thiazolo[3,2-]pyrimidinone (, , -), 1,2,4-triazole-6-quinoline-pyrido[2,3-]thiazolo[3,2-]pyrimidinone (-), and pyrido[2,3-]thiazolo[3,2-]pyrimidine-ethyl-(pyridine)-9-thiaazabenzo[]azulenone () derivatives was performed with high yields while evaluating antimicrobial activities.
Methods: A new series of quinoline-pyrido[2,3-]thiazolo[3,2-]pyrimidine derivatives were prepared using a modern style and advanced technology, resulting in high yields of these new compounds.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!